Wall Street brokerages expect BioLife Solutions, Inc. (NASDAQ:BLFS) to post earnings per share of ($0.06) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for BioLife Solutions’ earnings, with the lowest EPS estimate coming in at ($0.08) and the highest estimate coming in at ($0.05). BioLife Solutions posted earnings per share of ($0.04) in the same quarter last year, which would suggest a negative year over year growth rate of 50%. The company is scheduled to report its next quarterly earnings report on Thursday, November 4th.
According to Zacks, analysts expect that BioLife Solutions will report full year earnings of $0.06 per share for the current financial year, with EPS estimates ranging from $0.03 to $0.09. For the next year, analysts anticipate that the firm will report earnings of $0.09 per share, with EPS estimates ranging from ($0.22) to $0.36. Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for BioLife Solutions.
BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Wednesday, August 11th. The medical equipment provider reported ($0.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.03 by ($0.15). BioLife Solutions had a net margin of 4.72% and a negative return on equity of 0.07%.
In other news, CMO Todd Berard sold 6,165 shares of the business’s stock in a transaction on Thursday, July 15th. The shares were sold at an average price of $42.74, for a total transaction of $263,492.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Aby J. Mathew sold 715 shares of the business’s stock in a transaction on Tuesday, June 29th. The shares were sold at an average price of $43.75, for a total transaction of $31,281.25. Following the sale, the vice president now directly owns 209,589 shares of the company’s stock, valued at $9,169,518.75. The disclosure for this sale can be found here. In the last three months, insiders sold 200,943 shares of company stock worth $9,479,596. 5.90% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in the business. Marshall Wace LLP boosted its position in BioLife Solutions by 50.2% in the second quarter. Marshall Wace LLP now owns 1,766,692 shares of the medical equipment provider’s stock valued at $78,636,000 after buying an additional 590,659 shares during the last quarter. BlackRock Inc. lifted its position in shares of BioLife Solutions by 44.5% during the 2nd quarter. BlackRock Inc. now owns 1,896,772 shares of the medical equipment provider’s stock valued at $84,425,000 after buying an additional 583,954 shares in the last quarter. Palisade Capital Management LLC NJ purchased a new position in shares of BioLife Solutions during the 1st quarter valued at approximately $13,648,000. Millennium Management LLC lifted its position in shares of BioLife Solutions by 323.2% during the 1st quarter. Millennium Management LLC now owns 458,677 shares of the medical equipment provider’s stock valued at $16,512,000 after buying an additional 350,290 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of BioLife Solutions by 24.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,750,494 shares of the medical equipment provider’s stock valued at $77,915,000 after buying an additional 344,463 shares in the last quarter. Institutional investors and hedge funds own 68.31% of the company’s stock.
Shares of BLFS stock opened at $46.52 on Friday. BioLife Solutions has a one year low of $24.56 and a one year high of $60.67. The company’s 50-day moving average is $48.96 and its 200 day moving average is $41.05. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of 775.46, a price-to-earnings-growth ratio of 91.16 and a beta of 1.42. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 4.07.
About BioLife Solutions
BioLife Solutions, Inc engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services.
Further Reading: Death Cross
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.